布地奈德联合沐舒坦雾化吸入治疗小儿毛细支气管炎的疗效观察

Clinical efficacy of budesonide combined with mucosolvan via inhalation therapy on children bron-chiolitis

目的观察布地奈德联合沐舒坦雾化吸入治疗小儿毛细支气管炎的临床疗效。方法选取自2014年1月至2015年7月106例毛细支气管炎患儿，分为两组，每组53例，所有患儿均接受传统治疗小儿毛细支气管炎的综合治疗措施，治疗组53例患儿在综合治疗基础上加用布地奈德联合沐舒坦雾化吸入治疗，比较两组患儿症状体征缓解或消失时间、平均住院天数及治疗有效率等临床指标。结果治疗组患儿在症状体征小时或缓解时间均明显提前于对照组（P〈0．05）；治疗组患儿的平均住院天数少于对照组（P〈0．05）；治疗组患儿的治疗有效率为84．9％（45／53），对照组则为67．9％（36／53），差异均有统计学意义（P〈0．05）。结论布地奈德联合沐舒坦雾化吸入治疗小儿毛细支气管炎，可更加迅速的缓解症状，缩短病程，提高治疗有效率，其临床疗效显著，值得推广。

Objective To observe the clinical efficacy of budesonide combined with mucosolvan via inhalation therapy on children bronchiolitis. Methods A total of 106 children with bronehiolitis were divided into treatment group and control group, with 53 patients in each group. All patients underwent conventional comprehensive treatment, and on this basis treatment group received extra treatment with Mucosoivan combined with hudesonide inhalation therapy based on the comprehensive therapy. The signs and symptoms ease or disappear time, length of stay in hospital and the treatment efficiency of two groups were compared. Results The signs and symptoms ease or disappear time in the treatment group were significantly shorter than those in the control group （P 〈 0. 05 ） ; the average length of stay in hospital of treatment group was shorter than control group （P 〈 0. 05 ）. The treatment efficiency of treatment group was 84. 9% （45/53）, while that in the control group was 67.9% （36/53）, the difference was signifi- cant （P 〈 0. 05）. Conclusions Budesonide combined with Mucosolvan via inhalation therapy in treatment of children bronchiolitis can more quickly relieve symptoms and shorten the course of disease and improve treatment efficiency, its clinical effect is sisnificant, and it should be popularized.